Medical News / From AAO 2021: US Patient Access to Ophthalmology Clinical Trial Sites Differs by Regions

Access to US ophthalmology clinical trial sites may differ by region, according to new study findings that highlight the disparity of health care access among patients burdened with ophthalmic disease. In new data presented at the American Academy of Ophthalmology (AAO) 2021 Meeting in New Orleans this week, a team of investigators reported that patients in the Northeast may have better access to phase 3 clinical trial sites for ophthalmic care than other regions. The findings could implicate the validity and value of late-stage clinical trial findings—especially when considering the unique demographic and clinical factors impacting different regions of the US. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

According to new phase 3 data presented at the American Academy of Ophthalmology 2021 Meeting, brolucizumab ... read more
In an interview with HCPLive, Veeral Sheth, MD, Director of Clinical Trials, University Retina, discussed the ... read more
Although there are questions on the rationale behind step therapy, particularly for neovascular (wet) age-related macular ... read more
Over the weekend, important data on avacincaptad pegol treatment in patients from the GATHER1 clinical trial ... read more